India Pharma Outlook Team | Wednesday, 03 June 2026
Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil, marking a key milestone in its global regulatory expansion.
The CEP certification confirms that Akums’ manufacturing process complies with European Pharmacopoeia standards, enabling smoother access to regulated European markets and reinforcing its credibility as a global CDMO partner.
The approval positions Akums to strengthen its footprint in highly regulated markets, where compliance and traceability are critical. CEP certification serves as a globally recognised benchmark, allowing pharmaceutical companies to fast-track product registrations across Europe without undergoing redundant quality assessments.
For Akums, this not only improves market access but also enhances its attractiveness as a manufacturing partner for global pharma companies seeking reliable, compliant API suppliers.
Also Read: Indian CDMO 2.0 Guide: Risk-Sharing and Hybrid Models
The development comes amid increasing global demand for high-quality, regulation-compliant APIs. Growth in the API market is being driven by:
Rising prevalence of infectious diseases
Increasing demand for generic medicines
Tightening regulatory scrutiny in developed markets
Supply chain diversification by global pharma players
Cefpodoxime Proxetil, a widely used cephalosporin antibiotic, continues to see steady demand in treating bacterial infections, making regulatory approvals in this segment strategically important.
The CEP approval underscores India’s growing importance as a global hub for API manufacturing. With multinational companies looking to de-risk supply chains and reduce overdependence on single geographies, Indian CDMOs with strong regulatory capabilities are gaining prominence.
Akums’ latest approval reflects its ability to meet evolving international standards and aligns with broader industry trends where compliance-driven manufacturing is becoming a competitive differentiator.
The company highlighted that the achievement is a result of coordinated efforts across R&D, manufacturing, quality, and regulatory teams. It also aligns with Akums’ long-term strategy to expand its presence across Europe and other regulated markets.
Leadership emphasised that such approvals reinforce the company’s focus on delivering high-quality, affordable pharmaceutical products globally while maintaining stringent regulatory standards.
Akums’ CEP approval signals increasing competition in the regulated API space. For other CDMOs and API manufacturers:
Regulatory compliance is no longer optional but a key market entry requirement
CEP and similar certifications will become critical differentiators
Partnership opportunities with global pharma firms will hinge on quality benchmarks
Investment in advanced manufacturing and quality systems will accelerate
As more Indian players secure international certifications, the competitive landscape is expected to shift towards scale, compliance, and global integration.
Akums’ CEP approval for Cefpodoxime Proxetil marks a significant step in its global expansion journey, reinforcing its position in regulated markets while highlighting the growing importance of compliance-led growth in the global API industry.
Akums Drugs & Pharmaceuticals Ltd. is India’s largest CDMO, offering end-to-end solutions across formulation development, API manufacturing, and contract production, with strong regulatory capabilities and a growing presence in global regulated markets.
.jpg)
